脱敏治疗市场分析报告2015年.pdf

Desensitisation Therapy Market Report —— Potentiality Analysis for Desensitisation Prdocuts Dec 9th, 2010 Table of contents  Background (indications, incidence, market size) Page 3  Category selection and brand choices Page 7  IMS CHPA data analysis Page 12  Competitor intelligence Page 15  Summary of key findings Page 19 Page 2 Indications of Staloral other desensitisation products  Indications for immunotherapy in the treatment of allergic rhinitis based on the ARIA consensus and for the treatment of allergic asthma based on the WHO consensus: Intermittent (间隙性) Persistent (持续性) Mild Moderate/Severe Mild Moderate/Severe Rhinitis X √ √ √ Asthma X √ √ X  Contradictions:  Serious immune deficiency  Malignant disease  Treatment with beta-blockers, even those administered locally (drops)  Severe asthma uncontrolled by drug treatment (FEV1 =70% of the predicted value, even after drug treatment)  Non-compliant patient  Populations with relatively contradictions: children 5 years old, pregnant women Page 3 Asthma incidence and market size analysis  According to a epidemiologic survey in 2000, the incidence of Asthma among Chinese was about 1.2%. Of children 14 years old and elders 60 years old, the figures were 3.5% and 2.6% respectively. In addition, the CAGR of the incidence rate was estimated at 4%.  Therefore, its estimated that, of total popu